Nope, go back to Biogen board. No cuts coming. You guys have what? 3 reps in a territory on average the fifth size of ours? Look at what happened to Genzyme. Get back to your POD loser! By the way watch for new Gilenya indications this Fall.
Facts:
Gilenya market share is HORRIBLE for the 1st oral MS drug
Biogen has 3 MS products that are successful
Novartis lacks respect with the KOLs
The Gilenya launch was a disaster
The Primary care management style has not worked
Possible new indications do not lead to success to a product that is a hassle to prescribe
Shouldn't Dagmar and Sandy be first ones to go?
Shouldn't Dagmar and Sandy be first ones to go?
But we have super KAMs now....hahaha!
At NVS it's not a matter of if but when. Recent trends here don't look foot do field force retention. NVS has an extremely poor history in recent years of poorly launching products. A product life cycle is short enough today and can't recover from this trend. Field force always pays the price for mgmt mistakes. Gilenya fits right into this pattern and will alwAys be second fiddle on the market. First step will be not filling vacancies. Then the cuts will come. Plan B is always wise at NVS. Never let your guard down.
Ok either you nimrods are all independently wealthy or just plain suicidal. Why are you wishing for MS to cuts it's already small salesforce in half? And for those with a brain why the f$&@ would NVS do that in the eve of 2 new indications with over 2 billion in potential?
This place is specialty sales in name only. It's managed and run no differently than PCP.
How about todays call?? didnt seem to truthful.
Been in industry a long time with multiple global corps, launched multiple products. Gilenya launch one of the worst ever considering the product potential. no fault of the reps. Gross lack of understanding of physician / patient priorities; waited way too long to appeal to MS patients to drive demand; all patient education materials have been and continue to be horrible and so unbalanced that potential patients are scared away needlessly; etc. etc. But the scapegoat will be field sales. You can see it coming if you are paying attention. Sorry so gloomy but trying to keep it real.
If Biogen had launched Gilenya it would have over 20% market share by now. It's a good product, just completely mishandled. First oral agent for a patient population that was begging for a pill, yet launched with direction from product team not to mention that it's a pill!? Most convenient dosing regimen but don't mention convenience. Rare office that can do FDO themselves but wait months before supplying any outside FDO site, instead expect that each office will create a solution because of their strong conviction in Gilenya efficacy, regardless of whether they have the room or staff to handle it. Wow...Saying more would just be piling on.
